Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-12-27
2008-12-16
O'Hara, Eileen B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C530S387300
Reexamination Certificate
active
07465451
ABSTRACT:
The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
REFERENCES:
patent: 2953132 (1960-09-01), Richter et al.
patent: 3066671 (1962-12-01), Cohen
patent: 3608550 (1971-09-01), Stawski
patent: 3904482 (1975-09-01), Mehl
patent: 4024857 (1977-05-01), Blecher et al.
patent: 4116066 (1978-09-01), Mehl et al.
patent: 4300404 (1981-11-01), Mehl et al.
patent: 5516515 (1996-05-01), Vellucci et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 5880103 (1999-03-01), Urban et al.
patent: 5889151 (1999-03-01), Mogensen et al.
patent: 5919453 (1999-07-01), Benoit et al.
patent: 6475983 (2002-11-01), Eid et al.
patent: 6787634 (2004-09-01), Benoit et al.
patent: 7179465 (2007-02-01), Benoit et al.
patent: 0369877 (1990-05-01), None
patent: 0563487 (1993-10-01), None
patent: 2657881 (1991-08-01), None
patent: WO 91/05862 (1991-05-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/03538 (1992-03-01), None
patent: WO 92/18626 (1992-10-01), None
patent: WO 93/20187 (1993-10-01), None
Campbell, Monoclonal Antibody Technology, 1984, p. 1-30.
Ueno et al. J. Biol. Chem., 1999, vol. 266, 3146-3153.
Agnet et al. (1983) “Interferon 5.” (I. Gresser Ed.) pp. 1-22, Academic Press, London.
Benoit et al. “A Monoclonal Antibody to Recombinant Human IFN-α, Receptor Inhibits Biologic Activity of Severak Species of Human IFN-α, IFN-β and IFN-ω.” The Journal of Immunology, vol. 150, No. 3: 707-716.
Cantrell, K. et al. (1979) “Interferon 1.” I. Gresser Editor Academic Press: 2-25.
Colamonichi et al. (1990) “Characterization of Three Monoclonal Antibodies that Recognize the Interaction of α-2 Receptor.” Proceedings of the National Academy of Sciences of the USA. vol. 87, No. 18: 7230-7234.
Collins, S. J. et al. (1977) Nature. 270: 347-349. (Promyelocytic leukemia).
Dron, M. and M.G. Tovey. (1983) J. Gen. Virol. 64:2641-2647. (describes and antiviral assay as performed on Daudi cells).
Fazekas, S. et al. (1980) J. Immunol. Methods. 35: 1-32. (describes how 4 days after boosting, spleen cells from the immunized animal were collected and fused to NS1 (mouse) (Balbc) HGPRT myeloma cells).
Finter, N. B. and K. H. Fautes. (1980) Interferon 2. I. Gresser Editor Academic Press: 65-79.
Gresser, I. and M. G. Tovey. (1978) Biochem. Biophys. Acta. 516: 231.
Harris et al. (1993) TiBTECH, vol. 11: 42-44.
Hochuli, E. et al. (1988) Bio/technology. 1321-1325. (describes how the poly-histidyl tail introduced into the recombinant protein enables it to be purified rapidly by affinity chromatography on a chelated nickel support).
Klein et al. (1968) Burkitt lymphoma cell line. Cancer Research. 28: 1300-1310. (Burkitt lymphoma cell line; descibes How mAb secreted by the hybridoma line 64G12 50% inhibition of the binding of labeled IFN to the cells in a dose-dependent manner).
Klein, G. et al. (1972) Int. J. Cancer. 10:44-57. (describes how 50% inhibition was obtained for Ly28 cells at 60ug.ml).
Kohler and Milstein. (1974) Nature. 256: 495-497. (describes a construction protocol for hybridomas).
Langer et al. (1988) “Interferon Receptors.” Immunology Today. vol. 9, No. 12: 393-400.
Larrick et al. (1984) Bio Techniques. pp. 6-14.
Lozzio and Lozzio. (1975) Cell. 45: 321-334. (chronic myelogenous leukemia).
McGuinness et al. (1993) Lancet. 337: 514-517.
McGuinness et al. (1993) Mol. Microbiol. 7: 505-514.
Monoclonal antibody designated 64G12 under No. 92022605, deposited at the ECACC (European Collection of Animal Cell Cultures Porton Down Salisbury, Wiltshire SP4 056, United Kingdom) on Feb. 26, 1992.
Orten et al. (1970) Biochemistry. 8th Ed. The C.V. Mosby Company, St. Louis. pp. 57-90.
Riechmann et al. (1988) “Reshaping Human Antibodies for Therapy.” Nature. vol. 332: 323-327.
Streuli et al. (1981) Proc. Natl. Acad. Sci. USA 78: 2848.
Uze et al. (1990) “Genetic Transfer of a Functional Human Interferon Alpha Receptor into Mouse Cells: Cloning and Expression of its cDNA.” Cell. 60: 225-234.
Waldmann, T. (1991) Science. vol. 252: 1657-1662.
Weissmann and Weber. (1986) Proc. Nucl. Acad. Res. Mol. Biol. 33:251.
Yonehara et al. (1986) “Monoclonal Anti-Idiotype Antibody for Anti-Human Interferon-α that Complete with Interferon-α in Binding to Human Cell Surface and Inhabit the Interferon Action.” Elsevier Science Publication BV, pp. 167-171.
Benoit Patrick
Maguire Deborah
Meyer Francois
Plavec Ivan
Tovey Michael Gerard
Baker & Botts L.L.P.
Kim Yunsoo
Medarex Inc.
O'Hara Eileen B.
LandOfFree
Monoclonal antibodies against the interferon receptor, with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against the interferon receptor, with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against the interferon receptor, with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4031115